Positive results were achieved in the late-stage trial of Pfizer's combination therapy.

Pfizer and Astellas Pharmaceuticals announced that their drug Padcev, in combination with Merck's Keytruda, has achieved positive results in late-stage trials for the treatment of bladder cancer. The trial showed that this combination therapy significantly improved both progression-free survival and overall survival rates, paving the way for future regulatory submissions. This advancement will strengthen Pfizer's product pipeline in the field of oncology treatment.